Dementia

5 trials 3 recruiting MedDRA PT
5 Registered trials
3 Recruiting
5 Unique sponsors
4 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
J Anti-infectives (ATC J) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Vaccine 1 substance
Phase II: 2 Phase IV: 1 Phase I: 2

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase II

2 trials
  • Barcelonabeta Brain Research Center Academic
    [18F]DED
    2025-523284-37-00 1 country n=300
    Pending
  • Region Skane Academic
    2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE; FLUTEMETAMOL (18F)
    2024-511842-38-00 1 country 2017 n=2,450
    Recruiting

Phase IV

1 trial
  • GlaxoSmithKline Biologicals Commercial
    RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E
    2025-524598-17-00 1 country 2026 n=35,000
    Recruiting

Phase I

2 trials
  • Merck Sharp & Dohme LLC Commercial
    IMP not specified
    2026-525627-24-00 1 country 2026 n=16
    Recruiting
  • Therini Bio Inc. Commercial
    IMP not specified
    2024-517955-10-00 1 country 2023 n=96
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Merck Sharp & Dohme LLC Commercial 1 Phase I 1
Therini Bio Inc. Commercial 1 Phase I 0
GlaxoSmithKline Biologicals Commercial 1 Phase IV 1
Barcelonabeta Brain Research Center Academic 1 Phase II 0
Region Skane Academic 1 Phase II 1
New trials by year
2023
1
2026
2
← All indication landscapes